Skip to navigation Skip to main content Skip to footer

New technology has the ability to predict Coronary Heart Disease and Type 2 Diabetes

New technology has the ability to predict Coronary Heart Disease and Type 2 Diabetes

A new publication in Obesity journal contains ground-breaking data from AMRA Medical on its ability to predict the occurrence of disease in individual patients based on real-world evidence from the UK Biobank. Individualised data can be used to create virtual control groups and deeply enrich the patient populations selected in a clinical trial.

AMRA utilized medical data from 10,019 participants in the UK Biobank imaging sub-study. Advanced imaging analysis techniques were applied to the magnetic resonance imaging (MRI) data and body composition profiles, containing visceral and abdominal subcutaneous adipose tissue, muscle fat infiltration, and liver fat were analysed for each participant. Algorithms were applied to calculate individualized Coronary Heart Disease (CHD) and Type 2 Diabetes (T2D) propensities, or natural inclination, towards these diseases. In addition, the research explored how, in the clinically relevant areas of obesity and non-alcoholic fatty liver disease (NAFLD), metabolic disease phenotypes can be identified to describe an individual’s inclination towards CHD and T2D.

"UK Biobank’s success has allowed us to ask a lot more of our half a million volunteer participants – including inviting them to have full body scans. We have scanned almost 40,000 people and aim for 100,000. It is clear that these pictures are providing incredibly important information to a wide range of scientists who are getting on with the business of improving health. This new work, linking fat distribution and heart health, is based on just 10,000 images. Imagine the power of ten times that number of scans, which we will have in a few years’ time, to improve diagnosis and treatment of disease. We are very grateful to our participants for giving up their time to help create this exciting resource."

UK Biobank’s Principal Investigator, Professor Rory Collins